LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Elenco Azioni・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Chiusa

SettoreSettore sanitario

54.89 0.96

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

54.31

Massimo

55.05

Metriche Chiave
By Trading Economics
Entrata	1.6B 2.7B
Vendite	-1B 11B
P/E Media del settore	15.392 49.888
EPS	1.31
Rendimento da dividendi	4.37
Margine di Profitto	23.309
Dipendenti	32,500
EBITDA	1.5B 3.7B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+16.25% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	4.37% 2.38%
Utili prossimi	30 lug 2026
Prossima data del Dividendo	31 lug 2026
Prossima data del' Ex Dividendo	2 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-5.8B 112B
Apertura precedente	53.93
Chiusura precedente	54.89

Bristol-Myers Squibb Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 13:08 UTC

Utili

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12 mag 2026, 06:42 UTC

I principali Market Mover

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 apr 2026, 11:14 UTC

Utili

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29 mag 2026, 08:15 UTC

Discorsi di Mercato

Utili

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5 mag 2026, 18:12 UTC

Utili

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mag 2026, 13:54 UTC

Utili

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 apr 2026, 10:59 UTC

Utili

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 apr 2026, 14:13 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 12:57 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 11:19 UTC

Utili

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr 2026, 10:34 UTC

Utili

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 apr 2026, 21:23 UTC

Utili

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Confronto tra pari

Modifica del prezzo

Bristol-Myers Squibb Co. Previsione

Obiettivo di Prezzo

By TipRanks

16.25% in crescita

Previsioni per 12 mesi

Media 63.31 USD 16.25%

Alto 75 USD

Basso 40 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bristol-Myers Squibb Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Bristol-Myers Squibb Co. - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.